Semaglutide appears to safeguard the heart even when patients lose little weight. In a massive international trial, heart attack and stroke risk dropped by 20% regardless of BMI. The benefit seems ...
Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion ...
Founded in 2022 by Population Health Partners and ARCH Venture Partners, the biotech venture giant led by Bob Nelsen, Metsera ...
Explore the fierce competition between Novo Nordisk and Pfizer as they vie for Metsera amidst a booming obesity drug market.
Welltica+ on MSN
New study: Ozempic and Wegovy protect the Heart
A major international study led by researchers at University College London has found that semaglutide, the active ingredient ...
Judging from the numbers I'm seeing, the black market for weight-loss jabs isn't small-scale. This is a massive operation.
Danish pharmaceutical giant Novo Nordisk, maker of weight-loss drugs Ozempic and Wegovy, has announced an unsolicited bid to ...
TLDR Novo Nordisk launched an unsolicited $9 billion offer for Metsera, trumping Pfizer’s existing $7.3 billion acquisition ...
9h
‘I can't shake the anxiety about weight regain if I'm priced out of Mounjaro’: On life after GLP-1s
One writer felt she'd finally reached her bodily happy ever after via GLP-1 jabs. But with soaring prices and scientific unknowns on the horizon...now what?
Behind the glossy marketing and pharmaceutical assurances of GLP-1 medications lurks an underrecognized and potentially ...
Baron India Fund has outperformed the MSCI India Index by 660 basis points cumulatively since Fund conversion (effective September 1, 2024).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback